Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide vs hydroxyurea in high-risk essential thrombocythaemia
2004-004061-15Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in thrombocythemia comparing Anagrelide arm with Hydroxyurea arm (2 arms). Primary endpoint: Left ventricular ejection fraction (LVEF) slope over time. Started Jun 2005; status: completed.
02
Drugs
anagrelidehydroxyurea
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2004-004061-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004061-15.